Access and Accelerate Grant Program
Access and Accelerate Grant Program supports early-stage Massachusetts life science companies with commercialization expertise and services to reduce market barriers and advance innovations toward patients.
Funder: Massachusetts Life Sciences Center
Due Dates: October 30, 2026, at 1 p.m. EST (Q4 deadline) | January 2027 (Q1 application period) | March 2027 (Q2 application period)
Funding Amounts: Non-dilutive grants typically $75,000–$100,000, up to $150,000, for projects completed in approximately 6–12 months
Summary: Supports targeted commercialization expertise and services to help early-stage Massachusetts life science companies reduce market barriers and advance innovations toward patients.
Key Information: Applicants must not have raised more than $5 million in dilutive capital before submission.
Description
The Massachusetts Life Sciences Center’s Access and Accelerate Grant Program helps early-stage Massachusetts life science companies overcome go-to-market and commercialization barriers that are difficult to finance through traditional investment or research funding. Unlike traditional R&D grants, it supports specialized expertise and services that reduce commercialization risk, including market validation, regulatory planning, reimbursement strategy, manufacturing planning, and investor readiness.
The program aims to accelerate company growth, private investment, federal funding success, strategic partnerships, product development, and market readiness while strengthening Massachusetts’ life sciences ecosystem. Applications are accepted quarterly, with different sector focuses. The Q4 2026 cycle focuses on medtech and medical devices; future cycle focuses are to be determined.
